FiercePharmaOriginal article
{"a":[{"_":"AZ stays on track for $80B revenue goal as cancer meds help offset Ultomiris miss","$":{"href":"/pharma/az-stays-track-80b-revenue-goal-cancer-meds-help-offset-ultomiris-miss","hreflang":"en"}}]}
EarningsUltomirisPositive
AI Analysis
Summary
AstraZeneca reports confidence in achieving its $80 billion 2030 revenue goal despite trial setbacks and Ultomiris underperformance, with cancer medications helping offset near-term challenges.
Financial Highlights
Revenue
$80 billion
Guidance
2030 revenue goal of $80 billion on track
Importance:5/10
Sentiment:
0.30
revenue guidancepipelinecancer drugsfinancial outlooktrial setbacks
Related Companies
Read the original article
Published by FiercePharma on July 27, 2026 10:25 AM